Reuters logo
BRIEF-Hansa Medical develops second-generation IdeS molecules for repeat dosing
February 12, 2015 / 10:12 AM / 3 years ago

BRIEF-Hansa Medical develops second-generation IdeS molecules for repeat dosing

Feb 12 (Reuters) - Hansa Medical AB :

* Hansa Medical AB announced on Feb. 12 that the company is developing a new generation of molecules based on IdeS that will allow repeat dosing and thereby broadening the therapeutic opportunities into more chronic disease areas

* Says has patent protected new molecules Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below